Vaxess Technologies Tech Stack

Microarray patch platform for at-home pharmaceutical delivery without cold chain

Pharmaceutical Manufacturing Boston, MA 11–50 employees Founded 2012 Privately Held

Vaxess is a manufacturing-stage biotech company building proprietary microarray patches for home-delivered therapeutics. The stack reveals a precision-manufacturing operation: SAP for supply-chain planning, SolidWorks + 3D printing for prototyping, HPLC + LC-MS for drug characterization, and Rockwell Automation + MES for factory control. Active hiring is heavily skewed toward manufacturing (12 open roles) and operations, with R&D validation studies underway—a hiring pattern consistent with a company moving from proof-of-concept toward clinical readiness and commercial-scale production.

Tech Stack 15 technologies

Core StackSAP SolidWorks Python C++ Allen-Bradley Instron HPLC LC-MS MES Enzyme Veeva OpenCV Rockwell Automation Studio 5000 3D printing

What Vaxess Technologies Is Building

◆Challenges

Transitioning to late-stage clinical readiness
Ensuring efficient manufacturing operations
Building manufacturing capacity from the ground up
Manufacturing scale-up
Scalable gmp manufacturing systems
Reducing waste and costs
Improving system efficiency
High-throughput commercial scale manufacturing
Supporting integration of new processes
Functional map performance

▲Active Projects

Mes implementation
Manufacturing scale-up assessment
Master validation plans development
Scale up manufacturing operations
Develop machine vision inspection equipment
In vivo pk and safety studies in swine
High-throughput commercial scale manufacturing platform
Building manufacturing capacity
Characterization of microneedle array patch test articles
Process development experiments

Hiring Activity

Accelerating25 roles · 15 in 30d

Department

Manufacturing

Ops

Engineering

Research

Operations

Quality

Seniority

Senior

Mid

Junior

Company intelligence

Find more companies like Vaxess Technologies by tech stack, pain points and active projects

Get started free

About Vaxess Technologies

Vaxess develops a dissolvable microarray patch platform capable of delivering a range of therapeutic payloads without requiring refrigeration. The technology is designed to enable at-home administration and distribution to low-resource settings. The company has demonstrated clinical and in-vivo proof of concept across multiple molecule classes and has secured over $100 million in grant and venture funding from sources including RA Capital Management, Engine Ventures, GHIC, Mission BioCapital, BARDA, DARPA, NIH, NSF, and the Gates Foundation. Currently operating from Boston with 11–50 employees, Vaxess is in the midst of manufacturing scale-up, GMP validation, and late-stage clinical readiness work.

HeadquartersBoston, MA

Company Size11–50 employees

Founded2012

Hiring MarketsUnited States

Frequently Asked Questions

What is Vaxess Technologies working on?

Vaxess is scaling manufacturing operations for its microarray patch platform, running in-vivo pharmacokinetic and safety studies in animal models, developing master validation plans, building machine vision inspection systems, and establishing high-throughput commercial-scale GMP manufacturing capacity.

What tech stack does Vaxess use?

Vaxess operates a manufacturing and R&D stack: SAP (supply chain), SolidWorks (CAD), 3D printing (prototyping), HPLC and LC-MS (drug analysis), Veeva (pharma data), Rockwell Automation (factory control), and Python/C++ for analytics and machine vision.